Navigation Links
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Date:11/8/2007

Genasense Plus Temodar(R) and Abraxane(R) Show Promising Early Clinical

Activity

BERKELEY HEIGHTS, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) today announced the presentation of clinical data using the Company's lead oncology drug, Genasense(R) (oblimersen sodium) Injection in combination with Abraxane(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound; Abraxis BioScience, Inc.) and Temodar(R) (temozolomide; Schering Plough, Inc.) in patients with advanced metastatic melanoma. The study represents the rapid translation of preclinical results that demonstrated marked anticancer synergy with this drug combination. The results will be presented by Dr. Anna C. Pavlick, New York University School of Medicine, at the Chemotherapy Foundation Symposium XXV, entitled "Innovative Cancer Therapy for Tomorrow", at the Marriott Hotel, New York, NY on November 9, 2007.

To date, 8 patients have been accrued to this trial. Of the first 7 evaluable patients, 5 patients have demonstrated clinical benefit, including 3 partial responses that occurred after the first treatment cycle, which have lasted for 40, 24 and 16 weeks, respectively. Two other patients have maintained stable disease lasting for a minimum of 24 weeks. Two patients had progressive disease, and one patient is too early to evaluate. There have been no episodes of Grade 4 (i.e., life-threatening) side-effects. Four patients experienced Grade 3 leukopenia (i.e., reduction in white blood cell count), and 1 patient had Grade 3 thrombocytopenia (i.e., reduction in platelet count).

"Our goal with this trial is to evaluate the synergy of Genasense with drugs other t
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
3. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
4. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
5. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
6. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
7. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...if., Nov. 6 ,, 3Q0...r of Qutenza(TM) E.U. Marketing Authorization to A...ress in commercial readiness activities Expanded ...or, Marketing; and Director, Commercial Operations...or and Audit Committee chairman , Upcoming ...
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 Person...set to take place on February 22-24, 2010 in Phila...ference we will highlight key issues in forming pa...heir experiences. , Minne...for Arrowhead’s 2010 Personalized Medicine ...
(Date:11/5/2009)...J., Nov. 5 DSM Pharmaceutical Prod...ing alliance with Galenix, Saint Jean D,Illac, Fra...ale manufacturing partner for Galenix commercial p...ill collaborate on business development opportunit...s, based on the strength of Galenix in drug produc...
(Date:11/5/2009)...ov. 5 Transgenomic, Inc....ial results for the quarter ended September 30, 20...in the tables that follow. ,, Third Quarter 20...000 or $0.01 per share for the third quarter of 20...per share for the third quarter of 2008. ,, Ne...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...S Oncology Adjuvant Trial 9735 at 2007 San, Anton...Cyclophosphamide Improved Overall Survival Ver...c. 13 Results presented at the,30th annual San An...for,women with early stage breast cancer who have ...emotherapy combination of Taxotere(R) (docetaxel),...
...Valvulopathy Permitted to Enroll in 2nd and 3rd ...ment Eliminated, SAN DIEGO, Dec. 13 Arena Pharma...e initiation of patient screening in,the second an...cacy and,safety of its lead drug candidate, lorcas...eight and obese patients. Known as BLOSSOM (Behavi...
... Realty Trust, Inc.,(NYSE: BMR ) today announced ...rd of directors, increasing the board to eight mem...e industry, with a breadth of,ability and experien...operation of large-scale commercial real estate pr...r Board will be invaluable as we continue to,execu...
Other Biology Technology:Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 2Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 3Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 4Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 2Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 3Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 4Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 6BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 2BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 3
(Date:11/4/2009)...d obesity in the United States is reaching epidemi...ising on daytime and prime time television devoted...bout the role television plays in obesity, a study... Nutrition Education and Behavior examines how fo...contributor to the problem. , Researchers at the...
(Date:11/4/2009)...received more than $10 million in research grants ...stimulus program, bringing thetotal amount of stim...lion. Thirty-three projects achieved stimulus fun...er. , "The university has thoughtfully undertake...rly excellence to federal agency priorities. Thro...
(Date:11/4/2009)...wire/ -- DigitalPersona, Inc., a leader in fingerp...announced that WAND Corporation, a leading supplie...e restaurants, has integrated DigitalPersona techn...ions. WAND,s quick-service customers can now use f...ity and deter unauthorized manager overrides. As...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 2WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 3Income at Risk 3A Unemployment Skyrockets for Those with Disabilities Reports Allsup 59721 1Income at Risk 3A Unemployment Skyrockets for Those with Disabilities Reports Allsup 59721 2Income at Risk 3A Unemployment Skyrockets for Those with Disabilities Reports Allsup 59721 3Income at Risk 3A Unemployment Skyrockets for Those with Disabilities Reports Allsup 59721 4Income at Risk 3A Unemployment Skyrockets for Those with Disabilities Reports Allsup 59721 5New IOF report explains importance of FRAX in osteoporosis management 59716 1New IOF report explains importance of FRAX in osteoporosis management 59716 2Mice regain ability to extend telomeres suggesting potential for dyskeratosis congenita therapy 59711 1Mice regain ability to extend telomeres suggesting potential for dyskeratosis congenita therapy 59711 2
...ide in designated Special Areas of Conservation th...rnwall, might be at risk from pile driving. The fr...e with their ability to communicate, find food and... their behaviour, health and their ability to bree... might be particularly vulnerable , Recently more...
...nth,s issue of Angiology shows that supplementatio...en-all) improves blood flow to the muscles which s...of 113 participants demonstrated that Pycnogenol s...thletes and healthy, normal individuals. , "With ...a profound breakthrough and extremely significant ...
...e found that a method they developed to screen bod...eir genetic blueprint is twice as accurate at spot...ith a microscope. , The screen, developed by Sar... separates cells from fluid, then sifts through th...sociated with cancer. , Reporting in the June 1 ...
Other Biology News:South Pacific plant may be missing link in evolution of flowering plants 2Natural pine bark extract relieves muscle cramp and pain in athletes and diabetics 2Natural pine bark extract relieves muscle cramp and pain in athletes and diabetics 3Gene screen for breast cancer better than pathologist's 'eye' 2
...tabilCoat Plus Microsphere/Microarray Stabilizer i...ine protein and other non-toxic chemicals in a PBS... This product contains a combination of 0.02% meth...reservative. StabilCoat Plus Stabilizer provides ...
...Bgene's Protein Purification Plates are designed f...GE gels. The 96-well plates feature two 0.25mm hol... wells remain liquid-tight during incubation of th...otein diffuses from the gel into the buffer. Follo...
...bull; Small design specifically for western blots ...,Trays are specifically designed for staining west...he disposable tray requires less dye and antibodie...ser. Pour spouts in each corner facilitate pouring...
...he Gene Inspector can perform many sophisticated D...oftware is much more than just another sequence an...ne an entire suite of analyses to be performed eac...om style sheets which specify exactly how your out...
Biology Products: